Promising new therapeutic approach against Ebola virus identified

October 12, 2018, Mary Ann Liebert, Inc
Credit: Mary Ann Liebert, Inc., publishers

In a new study researchers have developed a two-pronged approach for targeting Ebola virus infection using linked nucleic acid (LNA) antisense oligonucleotides (ASOs)designed to interfere both genes essential for translation of Ebola virus genes and to block production of an intracellular human protein needed for the virus to enter cells. The results of using LNA ASOs to interfere with critical Ebola genes and host proteins are published in Nucleic Acid Therapeutics.

Anders Näär, Jessica Chery, Alexandre Wagschal, and Shobha Vasudevan, Massachusetts General Hospital Cancer Center (Charlestown, MA), and Harvard Medical School (Boston, MA), Andreas Petri and Sakari Kauppinen, Aalborg University (Denmark), and Sun-Yound Lim and James Cunningham, Brigham and Women's Hospital (Boston, MA) and Harvard Medical School (Boston) coauthored the article entitled "Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1."

The researchers described the distinct applications of LNA ASOs for this application. They demonstrated effective targeting of two Ebola viral genes -NP and VP24—which promote Ebola replication and inhibit a proper immune response against the , respectively. They also showed the ability to use LNA ASOs to prevent Ebola infectivity via a pathway that requires the host protein Niemann-Pick C1 (NPC1).

"This is the first application of LNA ASOs as a potential therapeutic strategy for the deadly Ebola virus, with multifarious advantages over the existing but as yet unapproved strategies," says Executive Editor Graham C. Parker, Ph.D., The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Explore further: New options for targeting gene mutation in FA described in nucleic acid therapeutics

More information: Jessica Chery et al, Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1, Nucleic Acid Therapeutics (2018). DOI: 10.1089/nat.2018.0722

Related Stories

New options for targeting gene mutation in FA described in nucleic acid therapeutics

March 8, 2018
Researchers have shown that a wide variety of synthetic antisense oligonucleotides with different chemical modifications can activate the frataxin gene, which contains a mutation that decreases its expression in the inherited ...

Researchers inhibit Ebola virus

December 29, 2017
The incurable Ebola virus has long been feared due to its high mortality rate and danger of infection. Now researchers from the University of Copenhagen and Phillips Universität Marburg have succeeded in inhibiting the virus ...

Scientists get first look at T cell responses in Ebola virus survivors

July 23, 2018
Scientists conducting the first comprehensive study of key immune system cells-collected from West African Ebola survivors-that kill Ebola infected cells have made a surprising discovery that provides important clues to developing ...

Silence is golden—Suppressing host response to Ebola virus may help to control infection

March 22, 2017
The Ebola virus causes a severe, often fatal illness when it infects the human body. Initially targeting cells of the immune system called macrophages, white blood cells that absorb and clear away pathogens, a new study has ...

Researchers identify protein role in pathway required for Ebola replication

July 26, 2016
A newly identified requirement of a modified human protein in ebolavirus (EBOV) replication, may unlock the door for new approaches to treating Ebola.

Recommended for you

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.